RecruitingNCT06524245

A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood

A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood: a Multi-center Study


Sponsor

Peking University Shougang Hospital

Enrollment

350 participants

Start Date

Jan 1, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

This multi-center study aims to develop a precise predictive model for colorectal cancer (CRC) recurrence and metastasis based on multi-omics analysis of portal vein blood. Despite advances in surgical treatments, approximately 40% of CRC patients experience tumor recurrence or metastasis post-surgery, with 80-90% of metastases being unresectable. The study will include stage I-IV CRC patients and will be conducted in two phases: a nested case-control study and a bidirectional cohort study. Comprehensive multi-omics sequencing will be performed on samples from primary tumors, adjacent tissues, normal intestinal tissues, portal vein blood, and peripheral blood. The goal is to identify specific biomarkers in the portal vein and peripheral blood associated with CRC recurrence and metastasis, and to compare the predictive accuracy of models based on these biomarkers. The ultimate objective is to provide a more effective method for early prediction and intervention of CRC recurrence and metastasis, thereby improving patient outcomes. Project Information: Project Title: A predictive model for recurrence of colorectal cancer based on multi-omics of portal vein blood: a multi-center study Project Duration: January 2020 to December 2026 Lead Institution: Peking University Shougang Hospital Principal Investigator: Gu Jin Contact: Hong Haopeng, 18059211195@163.com


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age 18 years or older
  • Histologically confirmed stage I-IV colorectal cancer (CRC)
  • Availability of pre-operative and intra-operative blood samples (portal vein and peripheral blood) and primary tumor tissue samples
  • No neoadjuvant therapy before surgery

Exclusion Criteria3

  • Prior history of other malignancies
  • Incomplete clinical information or pathology reports
  • Incomplete follow-up records

Locations(1)

Peking University Shougang Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06524245


Related Trials